Q-omics provides the consensus-scored ZNF702P profile across patient tissues and cancer cell-line models. ZNF702P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ZNF702P is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, ZNF702P RNA expression shows 18,846 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight OV, KICH, and THYM as cancer lineages where ZNF702P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF702P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF702P survival associations across molecular data types. ZNF702P RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF702P RNA expression–survival associations across cancer types. High ZNF702P expression shows unfavorable associations in LUSC, but favorable associations in OV, UVM, SKCM, UCS and KIRC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for ZNF702P RNA expression.
This table summarizes ZNF702P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF702P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF702P shows lower tumor expression in KICH and HNSC and higher tumor expression in BLCA, LUAD, STAD and BRCA. The KICH box plot shows higher ZNF702P RNA expression in normal versus tumor tissue (log2 FC = −2.118, t-test p < 0.001).
This table shows molecular features associated with ZNF702P in patient tissues and cancer cell lines. In patient samples, ZNF702P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF702P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH.
